| Title |
A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de- and re-challenge
|
|---|---|
| Published in |
International Journal of Clinical Pharmacy, July 2012
|
| DOI | 10.1007/s11096-012-9666-7 |
| Pubmed ID | |
| Authors |
Liesbeth Decoutere, Sabrina De Winter, Liesbeth Vander Weyden, Isabel Spriet, Maarten Schrooten, Jos Tournoy, Katleen Fagard |
| Abstract |
A 85 year old woman with a history of severe depression treated with mirtazapine and venlafaxine was admitted to the hospital twice after progressive deterioration of her general condition evolving to unconsciousness. Clinicians diagnosed a metabolic encephalopathy caused by a urinary tract infection which was treated appropriately. Although mirtazapine was stopped during the first hospitalization, the patient's general practitioner restarted mirtazapine four days before readmission. During rehospitalization, she developed extreme restlessness, hyperreflexia and an increased tone in the lower limbs. She was hypertensive and tachycardic. Excessive sweating, elevated creatine kinase levels and bilateral mydriasis were noticed. Urinary analysis showed positive levels of mirtazapine and venlafaxine and both drugs were withdrawn. Symptoms resolved within 48 h after discontinuation of her antidepressants. Conclusion To our knowledge, this is the first case of the serotonin syndrome confirmed by a positive challenge, de-challenge and re-challenge. |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 3% |
| Unknown | 28 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 6 | 21% |
| Student > Master | 5 | 17% |
| Student > Bachelor | 4 | 14% |
| Student > Ph. D. Student | 4 | 14% |
| Researcher | 4 | 14% |
| Other | 2 | 7% |
| Unknown | 4 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 45% |
| Nursing and Health Professions | 3 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Veterinary Science and Veterinary Medicine | 1 | 3% |
| Other | 3 | 10% |
| Unknown | 6 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2023.
All research outputs
#7,737,238
of 23,530,272 outputs
Outputs from International Journal of Clinical Pharmacy
#480
of 1,129 outputs
Outputs of similar age
#55,629
of 165,546 outputs
Outputs of similar age from International Journal of Clinical Pharmacy
#5
of 26 outputs
Altmetric has tracked 23,530,272 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,129 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 165,546 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.